Bristol Myers Squibb (CELG-RI) Retained Earnings (2009 - 2026)

Bristol Myers Squibb (CELG-RI) reported Retained Earnings of -$1.4 billion for Q1 2026, down 108.51% year-over-year from $16.1 billion in Q1 2025, and up 10.1% quarter-over-quarter from -$1.5 billion in Q4 2025.

Bristol Myers Squibb (CELG-RI) Retained Earnings (2009 - 2026) Analysis & Trends

Bristol Myers Squibb (CELG-RI) has 18 years of Retained Earnings data on file, last reported at -$1.4 billion in Q1 2026.

  • Retained Earnings for Q1 2026 came in at -$1.4 billion, down 108.51% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.4 billion (down 108.51% YoY), and the FY2025 annual result was -$1.5 billion, down 23.1% from the prior year.
  • Retained Earnings rose to -$1.4 billion in Q1 2026 per CELG-RI's latest filing, from -$1.5 billion in the prior quarter.
  • Over five years, Retained Earnings peaked at $25.5 billion in Q4 2022 and troughed at -$1.6 billion in Q2 2025.
  • A 5-year average of $7.4 billion and a median of -$1.2 billion in 2024 frame the typical range for Retained Earnings.
  • The sharpest annual moves came in 2024 and 2026: Retained Earnings surged 1351.71% in 2024, then plunged 108.51% in 2026.
  • A 5-year view of Retained Earnings shows it stood at $25.5 billion in 2022, then plunged by 106.06% to -$1.5 billion in 2023, then increased by 19.92% to -$1.2 billion in 2024, then dropped by 23.1% to -$1.5 billion in 2025, then climbed by 10.1% to -$1.4 billion in 2026.
  • Business Quant data shows CELG-RI's Retained Earnings at -$1.4 billion in Q1 2026, -$1.5 billion in Q4 2025, and $17.1 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Retained Earnings (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 1.90 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 29.51 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn -14.83 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn -17.87 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 66.72 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn -190.00 Mn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 78.00 Mn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn -7.20 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn -1.37 Bn
10 Bristol Myers Squibb - - 8.07 Bn -1.37 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 -1.37 Bn
Dec 31, 2025 -1.52 Bn
Sep 30, 2025 17.09 Bn
Jun 30, 2025 -1.55 Bn
Mar 31, 2025 16.11 Bn
Dec 31, 2024 -1.24 Bn
Sep 30, 2024 16.10 Bn
Jun 30, 2024 -1.46 Bn
Mar 31, 2024 15.64 Bn
Dec 31, 2023 -1.55 Bn
Sep 30, 2023 -1.29 Bn
Jun 30, 2023 -1.39 Bn
Mar 31, 2023 -1.37 Bn
Dec 31, 2022 25.50 Bn
Sep 30, 2022 24.68 Bn
Jun 30, 2022 24.22 Bn
Mar 31, 2022 -1.23 Bn
Dec 31, 2021 23.82 Bn
Sep 30, 2021 22.63 Bn
Jun 30, 2021 22.17 Bn